Name
Bevacizumab + IFL
Alternate names
FOLFIRIB
Primary Site
None
Histology
None
Radiation
None
Remarks
None
Drugs for Bevacizumab + IFL
Name
Alternate Names
5-Fluorouracil
5-Fluracil
Adrucil
Efudex
Fluoroplex
Fluracil
Fluril
Oracil
Ro 2-9757
WR-69596
Abbreviations
5-FU
5FU
FU
Category
Chemotherapy
Subcategory
Antimetabolite
NSC Number
019893
19893
Primary Site
Breast- adjuvant setting and advanced disease
colorectal- adjuvant setting and advanced disease
GI malignancies: anal, esophageal, gastric and pancreatic
Hepatoma
Ovarian cancer
Histology
None
Remarks
Fluorinated pyrimidine; antimetabolite. FDA approved uses on basal cell carcinoma, breast cancer, colorectal cancer, gastric cancer, and pancreatic cancer.
Note: Efudex cream be prescribed to treat AIN III. Code this as chemotherapy.
Note: Efudex cream be prescribed to treat AIN III. Code this as chemotherapy.
Coding
This drug should be coded
Name
Alternate Names
Avastin
rhuMAB-VEGF
Abbreviations
None
Category
Biologic therapy (BRM, immunotherapy)
Subcategory
Cytostatic agent--antiangiogenesis agent
Recombinant human anti-VEGF.
Vascular endothelial growth factor receptor inhibitor
NSC Number
704865
Primary Site
Breast- see remarks
Fallopian tube
Ovary
Peritoneum
colorectal
kidney
lung
multiple myeloma
Brain
Histology
None
Remarks
JANUARY 2013 IMPORTANT UPDATE: This drug has changed categories. A comprehensive review has been completed and in keeping with the FDA, this drug is to be coded as a Biologic therapy/Immunotherapy agent. Effective with diagnosis date January 1, 2013 forward, code Avastin as BRM/Immunotherapy. For cases diagnosed prior to January 1, 2013 continue coding this drug as chemotherapy.
FDA has formally revoked its approval of this drug to treat breast cancer. Physicians may still prescribe it but insurers may not pay for it.
FDA approved for colorectal cancer.
FDA approved for treatment of persistent, recurrent or metastatic cervical cancer in combination with paclitaxel and cisplatin or paclitaxel and topotecan.
Nov. 2014: FDA approved in combination with paclitaxel, doxorubicin, or topotecan for the treatment of patients with platinum-resistant, recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer.
In clinical trials Phase II and III for multiple myeloma
December 12, 2016: Avastin received FDA approval to be used either in combination with carboplatin and paclitaxel or in combination with carboplatin and gemcitabine chemotherapy, followed by Avastin alone, for treatment of patients with platinum-sensitive recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer.
6/15/18: FDA has approved bevacizumab (Avastin) for patients with epitheliĀ¬al ovarian, fallopian tube, or primary peritoneal cancer in combination with carboplatin and paclitaxel, followed by single-agent bevacizumab, for stage III or IV disease after initial surgiĀ¬cal resection
June 13, 2018: FDA approved bevacizumab (Avastin) for patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer in combination with carboplatin and paclitaxel, followed by single-agent bevacizumab, for stage III or IV disease after initial surgical resection.
December 6, 2017: FDA has granted full approval for Avastin (bevacizumab) for the treatment of adults with glioblastoma that progressed following prior therapy
FDA has formally revoked its approval of this drug to treat breast cancer. Physicians may still prescribe it but insurers may not pay for it.
FDA approved for colorectal cancer.
FDA approved for treatment of persistent, recurrent or metastatic cervical cancer in combination with paclitaxel and cisplatin or paclitaxel and topotecan.
Nov. 2014: FDA approved in combination with paclitaxel, doxorubicin, or topotecan for the treatment of patients with platinum-resistant, recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer.
In clinical trials Phase II and III for multiple myeloma
December 12, 2016: Avastin received FDA approval to be used either in combination with carboplatin and paclitaxel or in combination with carboplatin and gemcitabine chemotherapy, followed by Avastin alone, for treatment of patients with platinum-sensitive recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer.
6/15/18: FDA has approved bevacizumab (Avastin) for patients with epitheliĀ¬al ovarian, fallopian tube, or primary peritoneal cancer in combination with carboplatin and paclitaxel, followed by single-agent bevacizumab, for stage III or IV disease after initial surgiĀ¬cal resection
June 13, 2018: FDA approved bevacizumab (Avastin) for patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer in combination with carboplatin and paclitaxel, followed by single-agent bevacizumab, for stage III or IV disease after initial surgical resection.
December 6, 2017: FDA has granted full approval for Avastin (bevacizumab) for the treatment of adults with glioblastoma that progressed following prior therapy
Coding
This drug should be coded
Name
Alternate Names
Calcium folinate
Calcium leucovorin
Calcium leucovorin rescue
Citrovorum Factor
Citrovorum factor rescue
Folic acid
Folinic Acid
Lederfoline
Leucosar
Leucovorin Calcium
Leucovorin rescue
Wellcovorin
Abbreviations
C.F.
CF
CL
Category
Ancillary Agent
Subcategory
None
NSC Number
3590
003590
Primary Site
None
Histology
None
Remarks
The pharmacologically active form of folic acid. FDA approved uses as 1st line colorectal carcinoma in combination with 5-FU and to diminish methotrexate toxicity.
Coding
This drug should NOT be coded
Name
Alternate Names
Camptosar
Camptosar Oral
Camptothecin-11
CPT 11
CPT-11
CPT11
U-101440E
Abbreviations
None
Category
Chemotherapy
Subcategory
Topoisomerase inhibitor
NSC Number
616348
Primary Site
Colorectal
head & neck
Non-small cell lung cancer (NSCLC)
pancreatic cancer
Small cell lung cancer (SCLC)
Histology
None
Remarks
Phase I (head & neck) Phase III SCLC pancreatic Topoisomerase I inhibitor. FDA approved use on colorectal cancer. Pharmacia.
Coding
This drug should be coded